Biotech Values

[DewDiligence]

Welcome to the board, David. You present a good argument against Torcetrapib. However, PFE is spending more money on the Torcetrapib development program—by a wide margin—than any company has ever spent to develop any drug. If it fails, it will be perhaps the most colossal failure in the history of Big Pharma.

In short, I don’t think I would want to bet against PFE in this regard. Regards, Dew

p.s. I’m not sure I agree that only practitioners under the tutelage of Dr Nissen are qualified to perform IVUS. Rather, I think IVUS has become a mainstream procedure on account of its common use in clinical trials to evaluate drug-eluting stents.